Relay Therapeutics (RLAY) Total Current Liabilities (2019 - 2026)

Relay Therapeutics (RLAY) has reported Total Current Liabilities for 8 consecutive years, with $29.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Total Current Liabilities fell 19.7% year-over-year to $29.8 million; the TTM figure through Mar 2026 stood at $29.8 million (down 19.7% YoY), while the FY2025 annual figure was $25.6 million, down 49.58% from the prior year.
• Total Current Liabilities grew to $29.8 million in Q1 2026 per RLAY's latest filing, from $25.6 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $71.6 million in Q2 2023 and bottomed at $25.6 million in Q4 2025.
• Historically, Total Current Liabilities has averaged $46.0 million across 5 years, with a median of $43.9 million in 2022.
• Annual changes were most pronounced in 2022 — Total Current Liabilities jumped 161.95% — and 2023, when it tumbled 52.49%.
• Relay Therapeutics' Total Current Liabilities stood at $63.7 million in 2022, then sank by 52.49% to $30.3 million in 2023, then surged by 67.59% to $50.7 million in 2024, then slumped by 49.58% to $25.6 million in 2025, then climbed by 16.31% to $29.8 million in 2026.
• Business Quant data shows RLAY's Total Current Liabilities at $29.8 million in Q1 2026, $25.6 million in Q4 2025, and $32.6 million in Q3 2025.